Small-molecule tyrosine kinase inhibitors (TKIs) that block the adenosine triphosphate (ATP)-binding site of ABL1 represent the first- and second-line treatments of choice for most CML patients [3]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.